載入...

Belatacept Resistant Rejection is Associated with CD28(+) Memory CD8 T cells

Recently newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent is associated with superior patient survival and graft function than traditional therapy but its adoption as a m...

全面介紹

Na minha lista:
書目詳細資料
發表在:Am J Transplant
Main Authors: Mathews, DV, Wakwe, WC, Kim, SC, Lowe, MC, Breeden, C, Roberts, ME, Farris, AB, Strobert, EA, Jenkins, JB, Larsen, CP, Ford, ML, Townsend, R, Adams, AB
格式: Artigo
語言:Inglês
出版: 2017
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573634/
https://ncbi.nlm.nih.gov/pubmed/28502128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.14349
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!